Grufity logo
Grufity logo
APTO

APTO - Aptose Biosciences Inc Stock Price, Fair Value and News

$1.66 
Market Closed as of 06 Feb 2026, 04:00 pm ET

Price Targets

APTO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

APTO Price Action

Last 7 days

-1.2%

Last 30 days

27.3%

Last 90 days

17.7%

Trailing 12 Months

-70.9%

APTO RSI Chart

APTO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

APTO Valuation

Market Cap

4.2M

Price/Earnings (Trailing)

-0.15

Price/Free Cashflow

-0.17

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

APTO Fundamentals

APTO Earnings

Earnings (TTM)

-27.6M

Earnings Growth (Yr)

-37.72%

Earnings Growth (Qtr)

1.61%

APTO Profitability

Return on Equity

79.48%

Return on Assets

-257.01%

Free Cashflow Yield

-590.89%

APTO Investor Care

Shares Dilution (1Y)

20.04%

Diluted EPS (TTM)

-10.81

Revenue & Growth

How Aptose Biosciences Inc generates revenue and covers its expenses, based on the latest reported earnings.

About Aptose Biosciences Inc

APTO
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
 CEO
 WEBSITEaptose.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES35

Aptose Biosciences Inc Frequently Asked Questions

APTO is the stock ticker symbol of Aptose Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Apr 30 2026, market cap of Aptose Biosciences Inc is 4.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

In the past 10 years, Aptose Biosciences Inc has provided -0.475 (multiply by 100 for percentage) rate of return.